Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutritional-inflammatory-metabolic indices associated with in-hospital mortality in acute kidney injury patients undergoing continuous renal replacement therapy: dose-response analysis and machine learning-based risk stratification.

Frontiers in nutrition·2026
Same author

Entropy-Enabled Hierarchical Defect Architecture for Dual Enhancement of Thermoelectric and Mechanical Performance in SnTe Alloys.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

ELK3 promotes cisplatin resistance in ovarian cancer via regulating CHD4 gene expression.

Discover oncology·2026
Same author

Stabilizing Cubic GeSe via Metavalent Alloying for Enhanced Thermoelectric Performance.

ACS applied materials & interfaces·2026
Same author

Beyond NIHSS and neuroimaging: an interpretable gradient boosting model for predicting in-hospital mortality in ICU patients with acute ischemic stroke.

Scientific reports·2026
Same author

OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression.

International journal of biological sciences·2026

Related Experiment Video

Updated: Sep 13, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Elevated SLC4A11 expression promotes OV progression via interaction with EGFR.

Qihua Peng1, Yixuan Sun1, Ruiwen Wang1

  • 1Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Scientific Reports
|July 28, 2025
PubMed
Summary

Solute Carrier Family 4 Member 11 (SLC4A11) promotes ovarian cancer (OV) growth and metastasis by interacting with EGFR and activating the PI3K/AKT pathway. Targeting SLC4A11 may offer new therapeutic strategies for ovarian cancer.

Keywords:
EGFROvarian cancerPI3K/AKT pathwaySLC4A11

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Related Experiment Videos

Last Updated: Sep 13, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.8K

Area of Science:

  • Gynecological Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Ovarian cancer (OV) is a leading cause of cancer death, often diagnosed late with poor prognosis.
  • Standard treatments for OV, including surgery and chemotherapy, have limited efficacy against recurrence and metastasis.
  • Understanding the molecular drivers of OV progression is crucial for developing novel therapeutic targets.

Purpose of the Study:

  • To investigate the functional role of Solute Carrier Family 4 Member 11 (SLC4A11) in ovarian cancer (OV) progression.
  • To elucidate the molecular mechanisms by which SLC4A11 influences OV development.
  • To evaluate SLC4A11 as a potential therapeutic target for ovarian cancer.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets for SLC4A11 expression in OV.
  • In vitro functional assays (colony formation, migration, CCK-8) to assess the impact of SLC4A11 modulation on OV cell behavior.
  • In vivo subcutaneous xenograft mouse models to evaluate SLC4A11's role in tumor growth.
  • Mechanistic studies to identify SLC4A11's interaction partners and downstream signaling pathways.

Main Results:

  • SLC4A11 is significantly upregulated in OV tissues and associated with poor survival and advanced stages.
  • SLC4A11 overexpression enhances OV cell proliferation and migration; knockdown inhibits these processes.
  • SLC4A11 promotes tumor growth in vivo.
  • SLC4A11 directly interacts with Epidermal Growth Factor Receptor (EGFR), activating the PI3K/AKT signaling pathway.

Conclusions:

  • SLC4A11 acts as a key oncogene in ovarian cancer progression.
  • The SLC4A11-EGFR-PI3K/AKT axis is a critical pathway driving OV development.
  • SLC4A11 represents a promising therapeutic target for improving ovarian cancer treatment strategies.